Publications
NET RETREAT the CCTG NE1 trial has recently opened in North America looking to compare retreatment of Peptide Receptor Radionuclide Therapy versus standard treatment in patients with metastatic midgut neuroendocrine tumours.
Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MYELOMATCH Clinical Trials
Low and Anaplastic Grade Glioma Umbrella Study of Molecular Guided Therapies (LUMOS2)
Neoadjuvant Chemotherapy, Excision And Observation Vs Chemoradiotherapy For Early Rectal Cancer. The NEO-RT Trial
OptimICE-pCR: De-escalation of Therapy in Early-Stage TNBC Patients who Achieve pCR after Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Randomized Study of Nivolumab (Opdivo) or Brentuximab Vedotin (Adcetris) plus AVD in Patients (age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
MRD Driven Study of Venetoclax + Chemotherapy for Newly Diagnosed Younger Patients with Intermediate Risk AML
Novel Therapeutics in Younger Patients with High-Risk AML (MM1YA-S01)
Eradicating MRD in patients with AML prior to Stem Cell Transplant (ERASE)
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of ADjuvant ThErapy in URothelial CaNcer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
NEoadjuvant chemoradiotherapy for Esophageal scc vs Definitive chemoradiotherapy with salvage Surgery as needed (NEEDS Trial)
The Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) was published online today, August 20, 2019 and can be found on the Health Canada website at:
The CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a two Study Coordinators and a Research Associate.
Sites may record protocol training in the centre admin menu of the CCTG Site Training Utility (STU). CCTG has offered protocol-specific training for sites since 2012. To continue to be GCP compliant, protocol training has been required for all participants with delegated duties on the trial participants list for all new trials centrally activated after July 1, 2018. This requirement is stated in the Central Activation Letter and Notice of Health Canada Submission
Registration for the 2019 Canadian Cancer Research Conference (CCRC) is now open.The conference will be of interest to cancer researchers, clinicians, and decision-makers across disciplines and at all stages of their career.
CCTG Director, Dr Janet Dancey will be a Keynote Speaker at the The 5th International Clinical Trials Methodology Conference is being held 6-9th October 2019 in Brighton UK. Dr Dancey will be speaking on the The Evolution of Academic Sponsored Clinical Trials in the 21st Century: Lessons Learned at the Canadian Cancer Trials Group.
The Canadian Cancer Trials Group's (CCTG) Head and Neck Executive Committee (HNEC) is currently seeking individuals with interest and experience in head and neck studies to join the HNEC. In broad terms (adapted from the CCTG's Terms of Reference), the roles of the Disease Site Committee (DSC) Executive members are to:
Carol is a cancer survivor who was treated for metastatic gynecologic cancer in 2013. She has a network of other cancer survivors and patients who support each other during their cancer journeys. Today, Carol is currently a CCTG patient representative for the CCTG Gynecology, Economic Analysis and Clinical Trials committees. Carol is also the Managing Director, Audit Services at Ontario Teachers Pension Plan. Her career has included roles in finance, information technology, investments, risk management, external audit and (now) internal audit.
The Canadian Cancer Trials Group is seeking a Physician trained in a cancer-related specialty to join our research group as a Senior Investigator in the Investigational New Drug (IND) Program.